Alkermes' narcolepsy drug advances with positive Phase 2 results
Alkermes said its narcolepsy drug produced positive results in a Phase 2 trial, adding a potentially important development-stage asset to its portfolio. With no trial metrics or regulatory details disclosed here, the setup is constructive for the pipeline but not yet sufficient for a high-conviction earnings reset.
STOCK PHOTO · STAR ZHANGThe story
Alkermes' narcolepsy drug delivered positive results in a Phase 2 trial reported August 24. The asset adds to the pipeline of ALKS, whose FY 2025 revenue was $1.5B, down 5.2% YoY, with a 16.4% net margin and $1.43 diluted EPS. The concrete mechanism for the stock is therefore pipeline value: a successful program could broaden the company's future revenue base, while the current operating figures show that the market still has an established commercial business against which to measure the asset.
The next catalysts are fuller Phase 2 data, management's comments on durability and safety, and any decision to advance the program into late-stage testing. Key unknowns remain regarding how differentiated the drug is, how large the addressable opportunity could be, and how much development and regulatory work remains.
Our read · Mon, Aug 24
Alkermes (ALKS) said its narcolepsy drug produced positive results in a Phase 2 trial.
Why. The near-term value driver is optionality around a new narcolepsy program, layered onto ALKS’s $1.5B revenue base. That read is constructive, but the absence of efficacy, safety, and study-design details makes the likely magnitude of any repricing uncertain and argues for a modest target and tight risk definition.
Both cases
What could change this view: A weak or incomplete Phase 2 dataset, safety signal, or delay in advancing the program would remove the pipeline catalyst while the existing business is already showing 5.2% YoY revenue decline.
Who reported it · 1
Keep reading
Latest on the Wire
Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsContinue on the Wire →Latest on the Wire
Poland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Investing.com as Alkermes narcolepsy drug shows positive phase 2 trial results
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →